

Curriculum Vitae



Naghmeh Hadidi: Pharm. D., Ph. D. of Pharmaceutics

Department of Physiology & Pharmacology

Pasteur Institute D' Iran, No. 69, Pasteur Ave., Tehran, Iran

Email: n_hadidi@pasteur.ac.ir or hadidi@gmail.com

Tel: (0098) 2188906689, 2166496753, 9122054655

Fax: (0098) 21 88541697

Objectives:

I am interested to be involved and have collaboration with a nanobio research group and academic departemnt who is leading and innovativie in the field designing novel drug delivery systems.

I am also interested to be involved or have consultant with strategic decision making and pipeline management of pharmaceutical companies. I am very keen on having collaborative work with research groups who are leading and innovative in the field pharmaceuticals, biopharmaceutical, nanobiopharmaceuticals, neutraceuticals or novel drug delivery systems. This will enable me to utilize my experiences and skills in market research studies, pharmaceutical products formulation and scale up for industrialization of pharmaceuticals and biopharmaceuticals.

Education:

2006 –to 2012

PhD in Pharmaceutics, School of pharmacy, Shaheed Beheshti

University of Medical Sciences (SBMU), Tehran, Iran

Thesis: Preparation and Evaluation of Cyclosporine-Loaded Carbon Nanotubes as a Novel IV Dosage Form with Optimized Physico-Chemical Properties and Increased Efficiency

1999-2005 Pharm. D. (Doctor of Pharmacy), School of Pharmacy, Shaheed Beheshti

University of Medical Sciences (SBMU), Tehran, Iran

Thesis: Formulation and Optimization of Physostigmine Salycilate Sublingual Tablet

Professional Experience:

April 2015 till present

Head of clinical trial and Electronic Microscope, Pasteur Institute of Iran, Tehran, Iran

June 2015 till present

Production Deputy of Bacterial Recombinant Production Plant, Pasteur Institute of Iran, Karaj, Iran

September 2014 till present

Head of Drug Committee in Health Technology Council of Iran Ministry of Health, Tehran, Iran

June 2015 till present

Managing Director and Member of the Board in GMP, a Private Knowledge-based Company on Biopharmaceuticals and Antivirals, Tehran, Iran

January 2014 till present

Formal Representative of Pasteur Institute of Iran in MOH Managing Committee of Feasibility Studies and Commercialization of Pharmaceutical Priorities in Iran, Tehran, Iran

October 2013 till present

Consultant of Minister of Health Consultant in Health Technology Committee, Tehran, Iran

October 2013 till present

Consultant of General Director of Pasteur Institute of Iran in Technology affairs, Tehran, Iran

September 2013 till present

Cooperation with Ramsar International School of Pharmacy for Teaching Courses in Pharmaceutical Sciences, Ramsar, Mazandaran

September 2013 till present

Assistant professor, Physiology-Pharmacology Department, Pasteur Institute of Iran, Tehran, Iran

May 2013 till September:

Manager of of Business Development Department, Shafapharmed, Shifagroup, Tehran, Iran

Jan 2013 till May 2013:

Manager of market Research and Clinical Trial Department, Osvah Pharmaceutical Company, Tehran, Iran

May 2011 till 2013:

Head of market Research and Clinical Trial Department, Osvah Pharmaceutical Company, Tehran, Iran

Dec. 2005 to 2011

Formulator of pharmaceutical dosage forms (tablets, capsules, injections,...)
R&D Department, Osvah Pharmaceutical Company, Tehran, Iran

March 2009 to 2011:

Member of Leading Committee of Development (Design and construction of new production facility for parenterals (vials-PFS), Osvah Pharmaceutical Company, Tehran, Iran

June 2006 - 2008:

Member of Development Committee (Design and construction of new production facility for anticancer dosage forms, Osvah Pharmaceutical Company, Tehran, Iran

September 2007 to 2011:

Supervisor of Market Research Committee (MR Committee), Osvah
Pharmaceutical Company, Tehran, Iran

Experiences and Expertise in Laboratory Techniques:

Nearly 11 years of Experience in Pharmaceutical Industry Including Resreach and Development, Project Manager, Technology Transfer, Industrial Scale up, Product Selection, Product Registration of Bio/Pharmaceuticals , Clinical Trial Registration and Supervision, Contract Manufacturing, Agreement-CDA-LOI-MOU Revising.

3 years of teaching experience for Pharm.D. and PhD Students.

3 years of Experience in Bacterial Based Recombinant Proteins (Interferon Alfa-2b, Streptokinas, Somatropin) Production Including Upstream and Downstream.

6 years experience in formulation of different dosage forms (tablets, capsules, etc.) and preparing DMFs (Drug master Files) to be licensed by Iran MOH (Ministry of Health) being distributed in internal market and some have been exported.

Formulation of 15 pharmaceutical products including chemicals, supplements and anticancer medicines (Rivaroxaban 10 mg, Valsartan 80mg & 160 mg, , Raloxifene 60 mg, Rosuvastatin 10 mg, 20 mg, 40 mg, Day vitamin prenatal, Day vitamin plus, Heartsupplement, Imatinib 100 mg, Exemestane 25 mg, Simvastatin 10 mg/ Ezetimibe 10 mg, Simvastatin 20 mg/ Ezetimibe 10 mg, Q10 100 mg)

Industrial scale up of 7 pharmaceutical products including Valsartan 80 mg & 160 mg, Raloxifene 60 mg, Day vitamin prenatal, Day vitamin plus, Imatinib 100 mg, Exemestane 25 mg.

Formulation optimization and correction management of 3 industrial products (lisinopril 5mg & 10 mg, Lovastatin 20 mg)

Supervision of formulation, analysis and DMF preparation of 21 pharmaceutical products including: Rivaroxaban 10 mg, Valsartan 80mg & 160 mg, , Raloxifene 60 mg, Rosuvastatin 10 mg, 20 mg, 40 mg, Day vitamin prenatal, Day vitamin plus, Heartsupplement, Imatinib 100 mg, Exemestane 25 mg, Simvastatin 10 mg/ Ezetimibe 10 mg, Simvastatin 20 mg/ Ezetimibe 10 mg, Q10 100 mg, Influenza vaccine, Glatiramer 20mg/ml, Reteplase 10.4IU/ml, Temozolomide 20 mg, 100 mg, 250 mg,

Preparation of investigational pharmaceutical market outlook and perspectives for 9 therapeutic fields (Multiple Sclerosis, Antithrombotics, Antihypertensives, Antirheumatoids, Antioxidants, MABs, Osteoporosis, and Novel Drug Delivery Systems, Neutraceuticals suitable for Iran market,).

Preparation of pharmaceutical market trends reports (until 2009) in order to be used for strategic pipeline management of Osvah Pharmaceutical Company.

Supervision, preparation and presentation of 53 analytical reports about novel drug products and technologies for selection, pipeline management and determination of future strategies in Osvah Pharmaceutical Company. The most recent reports are about market feasibility studies of Monoclonal antibodies (new generations), Pentosan, Neurobion fort, Strontium renolate, Ivabradine, Naltroxane combinations, Nanosilver technology, Oxycodone combinations, Temisirolimus, Therapeutic ODTs, Gefitinib, Pemetrexed, Presugrel, Ticagrelor, Aranesp, Tygecycline, Cancer overview in Iran, Thyrosine kinase inhibitors and sodium alginate.

Supervision of reviewing, production planning and DMF preparation of biopharmaceuticals (Glatiramer acetate, Reteplase, Influenza vaccine)

Supervision and assistance in construction of a comprehensive data base consisted of pipelines of global pharmaceutical companies' products and technologies.

Supervision in bench marking project for reviewing similar pharmaceutical companies around the world, SWOT analysis and strategies' recommendation for overall improvement of Osvah pharmaceutical company.

Preparing business plan about liposomal drug delivery for Osvah pharmaceutical company. The report includes marketed liposomal drug deliveries, market research studies, product selection, price estimation with a reasonable profit margin and minimum required industrial batch size for three years.

Assistance in project planning (production and analysis set up) of Influenza Vaccine in Osvah Pharmaceutical Company.

Supervision in preparing SOP (Standard Operating Procedure) for methodology designing, establishment, inspection, follow ups and reporting for clinical trial studies for Osvah pharmaceutical company.

Major assistance in designing methodology and follow ups of A randomized, multicenter study evaluating safety of Fingolide® in patients with (RRMS) Remitting-Relapsing Multiple Sclerosis.

Major assistance in designing methodology and follow ups of safety and efficacy study of Reteplase (recombinant plasminogen activator) in patients with Acute Myocardial Infarction & ST segment elevation.

Major assistance in designing methodology and follow ups of safety and efficacy study of Cytogan® (mychophenolate mofetile tablet 500 mg) in Patients Receiving Allograft Transplantation.

Analysis of drugs in biological and pharmaceutical samples using analytical methods like HPLC, LC-MS, SEC, and Gas Chromatography

Biological studies of drugs using cell culture techniques (cell count, viability tests, MTT assay and flow cytometry)

10 years experience in using optimization statistical software (Design Expert version 6 & 7) in designing of different process

Being closely involved in designing and validation of cleaning process (cleaning validation) of anticancer drugs in a pharmaceutical manufacturing plan.

Major assistance in writing a research proposal on industrial scale up of Reteplase for Osvah pharmaceutical company,

Major assistance in writing a research proposal on industrial scale up of liposomal Glutathione for Osvah pharmaceutical company.

Has used statistical methods (DOE-Design expert, Prism, and SPSS) for more than 6 years.

Introducing DOE based on Design Expert software in a 2-days workshop

Experience in working with digital viscometer (Brookfield-cone and plate) ,hardness testing instrument, disintegration instrument, dissolution instrument, friability instrument, rotary tablet press machine, powder flow meter)

Awards and Honors:

- 2015:** First ranked oral lecturer in IPSC 2015, Tehran,Iran
- 2014:** Vistatropin Brand Registration, No. 236583
- 2013:** Internal Patent Registration, No. 83149
- 2012:** Supervised Osvah market research and clinical trial department has been selected as best practice among Iran pharmaceutical companies.
- 2010:** Being selected as high ranked unique personnel in Osvah Pharmaceutical Company from R&D Department
- 2008:** Second ranked in Comprehensive PhD Board of Pharmaceutics, School of Pharmacy, SBMU.
- 2006-2007:** Supervisor of Pharmacy Students Research Committee, School of Pharmacy, SBMU.
- 2006-2007:** Formal representative of Medical Students Research Committee from

Shaheed Beheshti School of Pharmacy

- 2006:** Reviewer in 7th National Congress of Medical Student, SBMU.
- 2006:** Member of the Executive Committee of the 7th Iranian Medical Science Student Conference
- 2006:** Being granted the annual honorary award certificate of Shaheed Beheshti School of Pharmacy
- 2005-2006:** Informal member of the Executive Committee of the Iranian Journal of Pharmaceutical Research (IJPR) for 2 years
- 2005:** Young Investigator 1st Award from 6th National Conference of Medical Students, Sari, Iran
- 2005:** Being selected as a high-ranked unique pharmacy student regarding educational and research fields in Shaheed Beheshti School of Pharmacy
- 2005:** Being selected as a high-ranked unique pharmacy student regarding educational and research fields in SBMU.
- 2005:** Achieve 2nd ranking of MCHE exam with grade of 84 (out of 100)
- 2005:** Being graduated from Shaheed Beheshti School of Pharmacy with the average grade of 17.58 (out of 20) as Pharm. D.
- 2004** Being selected by Iran Ministry of Health (MOH) as a high-ranked top student regarding educational and research fields among national Medical Universities
- 2004:** Young Investigator 2nd Award from National Conference of Pharmacy Students, Tabriz, Iran
- 2000:** FCE (First Certificate in English) certificate with grade B from University of Cambridge local examination syndicate
-

Research Grants

Research grant from Pharmaceutical Research Center, Shaheed Beheshti University of Medical Sciences: The title of this grant was “Formulation and Optimization of Physostigmine Sublingual Tablet”. This project started in January 2003 and finished after one year.

Research grant from Pharmaceutical Research Center, Shaheed Beheshti University of Medical Sciences: The title of this grant was “Formulation and Optimization of Captopril Sublingual Tablet”. This project started in January 2003 and finished after one year.

Research grant from Tissue Engineering and Nano Research Center, Shaheed Beheshti University of Medical Sciences,: The title of this grant was: “Investigation of Surfactants Efficiency and Efficacy in Solubility and Biocompatibility Improvements of Carbon Nanotubes in Biological Systems”. This project has been started from September 2009 for 18 months.

Research grant from Iran National Science Foundation: The title of this grant was: “Preparation and Evaluation of Cyclosporine-Loaded Carbon Nanotubes as a Novel IV Dosage Form with Optimized Physico-Chemical Properties and Increased Efficiency”. It has been started from September 2009 for 24 months.

Research grant from Iran National Science Foundation: The title of this grant was: Meta analysis study and perspective of innovative pharmaceutical trends by therapy class from 2000-2020 .It has been started from December 2010 for 24 months.

Research grant from Deputy of Research and Technology, Pasteur Institute of Iran: Preparation , Evaluation and Optimization of COOH- functionalized Single-Walled Carbon Nanotubes on Viability and Proliferation of HEPG2 and A549 cell lines. It has been started from January 2013 for 18 months

Research grant from Deputy of Research and Technology, Pasteur Institute of Iran: The title of this grant was Industrial manufacturing of Bioindicators for validation qualification of sterilization in Autoclaves. It has been started from February 2014 for 24 months

Research grant from Vice President for Science and Technology: The title of this grant was Synthesis and Semi-Industrial production of valganciclovir API and Tablet as a preventive treatment for CMV and herpes simplex. It has been started from June 2015 for 9 months

Research grant from Vice President for Science and Technology: The title of this grant was Synthesis and Semi-Industrial production of parenteral antiviral drugs (ganciclovir) Iin HRCT patients. It has been started from July 2016 for 12 months

Research grant from Deputy of Research and Technology, Pasteur Institute of Iran: The title of this grant was Preparation and Evaluation of a Novel Drug Delivery System Base on Transferosome for Lactoferrin as a Topical Treatment for Genital Warts Caused by Human Papiluma Virus (HPV). It has been started from Aug 2015 for 18 months.

Research grant from Deputy of Research and Technology, Pasteur Institute of Iran: The title of this grant was Preparation, optimization and toxicity evaluation of functionalized carbon nanotubes in RAW 264. 7 as novel vaccines adjuvants. It has been started from June 2016 for 18 months.

Fellowships and Workshops:

2015: Workshop on Nanobiotechnology and its Indication in Drug Delivery, Pasteur Institute of Iran, Tehran, Iran

2014: Workshop on Commercialization and Marketing of Pharmaceuticals, Pasteur Institute of Iran, Tehran, Iran

2012: Workshop on Good Clinical Practice (GCP), 12th International Immunology Conference, Tehran, Iran

2012: Seminar on Iran clinical trials' referees and inspectors by Iran FDO (Food and Drug Organization), Tehran, Iran

2011: Workshop on Molecular Detection of Mycoplasma in Cell Culture by PCR, Iran APS & Razi Vaccine and Serum Research Institute, Tehran, Iran

2011: Workshop on Branding in Pharmaceutical Industry, Pharmacy School, Tehran University of Medical Sciences

2010: Workshop on Light Scattering (Nanosizer and Zetasizer for practical applications) Research Institute of Petroleum Industry (RIPI), Tehran, Iran

2010: Workshop on Rapid Analysis with HPLC (UHPLC), IPSC2010, Zanjan, Iran

2010: Workshop on Global Pharmaceutical Industries, IPSC2010, Zanjan, Iran

- 2010:** Workshop on Nanogel, IPSC2010, Zanjan, Iran
- 2010:** Workshop on LC-MS Fundamentals and Applications, Shaheed Beheshti School of Pharmacy, Tehran, Iran
- 2010:** Workshop on Screening and Optimization (Focused on Design Expert software) Shaheed Besheshti School of Pharmacy, Tehran, Iran
- 2010:** Workshop on GMP of Ventilation Systems in Pharmaceutical Industry, Osvah Pharmaceutical Company, Tehran, Iran
- 2010:** Workshop on General Management Osvah Pharmaceutical Company, Tehran, Iran
- 2009:** Workshop on Iran and Global Pharmaceutical Market, Opportunities & Challenges, Shaheed Besheshti School of Pharmacy, Tehran, Iran
- 2009:** Workshop on Current Challenges in Drug Development Regulatory Affairs, Shaheed Besheshti School of Pharmacy, Tehran, Iran
- 2009:** Workshop on Cell Culture Techniques, Shaheed Besheshti School of Pharmacy, Tehran, Iran
- 2008:** Seminar Drug Therapy in Pigmentation Disorder, Tehran, Iran
- 2008:** Seminar in Drug Therapy in Cancer and Blood Diseases, Tehran, Iran.
- 2008:** Seminar in Drug Therapy in Cardiovascular Diseases, Tehran, Iran
- 2007:** Workshop on Pharmaceutical Biomaterials, 1st international Conference on Biomaterials, IBB, Tehran, Iran
- 2006:** Workshop on HPLC Troubleshooting, Osvah Pharmaceutical Company, Tehran, Iran
- 2006:** Workshop on Analytical HPLC, Osvah Pharmaceutical Company, Tehran, Iran
- 2006:** Workshop on Monoclonal Antibodies Production, AVECINA Center, Shaheed

Beheshti University of Medical Sciences, Tehran, Iran

2006: Workshop on Stability Tests for Biopharmaceuticals, CinnaGen co.
Tehran, Iran

2003: Workshop on Molecular Techniques in Physiology, 16th Congress of
Physiology and Pharmacology, Tehran, Iran

Memberships and Academic Services:

Reviewer in Iranian Journal of Pharmaceutics (IJPR) (2009 to present)

Informal Member of Executive Committee of Iranian Journal of Pharmaceutical Research (2005 to 2006)

Member of Research & Development, Osvah Pharmaceutical Company (2005 to present)

Member of Market Evaluation Committee, Osvah Pharmaceutical Company (2007 to present)

Member of Iranian Society of Controlled Release Systems (CRS)

Member of Iranian Association of Pharmaceutical Scientists

Member of the Executive Committee of the 7th Iranian Medical Science Student Conference

Peer-Reviewed Publications:

1. Evaluation of the cytotoxicity of original and functional carbon nanotubes in human lung cells, **Hadidi N**, Ramezani L, Saffari M, Feyz 2015; 19(4): 326-33.
2. The effect of surface modification of single-wall carbon nanotubes on cytotoxicity reduction in the liver cell model (HEPG2), **Hadidi N**, Ramezani L, Shokrgozar MA, Amanzadeh A, Saffari M, Feyz 2015; 19(4): 301-8.
3. **Hadidi N.**, Kobarfard F., Nafissi-Varcheh N., Aboofazeli R., PEGylated Single-Walled Carbon Nanotubes as Nanocarriers for Cyclosporin A Delivery, AAPS PharmSciTech 2013, 14 (2): 593-600
4. **Hadidi N.**, Hosseini Shirazi S.F., Kobarfard F., Nafissi-Varcheh N., Aboofazeli R., Evaluation of the Effect of PEGylated Single-Walled Carbon Nanotubes on Viability and Proliferation of Jurkat Cells, Iranian Journal of Pharmaceutical Research, 2011, 11(1): 27-37.

5. **Hadidi N.**, Kobarfard F., Nafissi-Varcheh N., Aboofazeli R., Optimization of Single- Walled Carbon Nanotube Solubility by Noncovalent PEGylation Using Experimental Design Methods, *Int. J. Nanomedicine*, 2011,6:737-746
6. **Hadidi N.**, Nazari N., Aboofazeli R., Formulation and Optimization of Microemulsion-Based Organogels Containing Propranolol Hydrochloride Using Experimental Design Methods,*Daru*,2009, 17(3) : 217-224
7. Bolourtchian N. , **Hadidi N.** , Foroutan S.M. , Shafaghi B. ,Development and Optimization of a Sublingual Tablet Formulation for Physostigmine Salicylate, *Acta Pharmaceutica* 2009, 59(3):301-12.
8. Bolourtchian N. , **Hadidi N.** , Foroutan S.M. , Shafaghi B. , Formulation and Optimization of Captopril Sublingual Tablet by D-optimal Design,*IJPR* ,2008,7(4):259-267
9. Sayyah M.; **Hadidi N.**, Kamalinejad M., Analgesic and Anti-inflammatory Activity of Lactuca Sativa Seed Extract in Rats ,*J Ethnopharma* ,2004 ,92 (2-3):325-9

Books (in Persian):

1. **Hadidi** etal., Resilience Economics: 2nd part: Achivenments and performance in 2014, Iran MOH, 2015 (Author and Editor)
2. **Hadidi** etal., Resilience Economics: 1st part: Pharma industry, Iran MOH, 2014, (Author and Editor)
3. Mortazavi S.A., **Hadidi N.**, Saffari M., Ghaffari A. A Review on Powders' Characteristics as Pharmaceutical Excipients: Particle Engineering & Second Generation of Pharmaceutical Excipients, 2008 (Author)

Abstracts:

1. Aqueous cationic and anionic surface functionalization of single-walled carbon nanotubes for biomedical application and drug delivery, **Hadidi N.**, Saffari M., 4th International Conference on Nanotechnology and Basic Science ,ICN2016, Dubai. Emirates.
2. Identification and prioritization of effective elements on resilience economic in phamra industry, **Hadidi N.** Rahimi S., 2nd National Conference on Applied Economics and Management, June 2015, Sari, Iran
3. Aqueous surface functionalization of single-walled carbon nanotubes for biomedical applications , **Hadidi N.** IPSC2015, Tehran, Iran.

4. Drug targeting outlooks in 1410, **Hadidi N.**, 11th congress of pharmacists association, Tehran, Iran.
5. Single-Walled Carbon Nanotube as a Novel Drug Delivery System for cyclosporine, **Hadidi N.**, Kobarfard F., Nafissi-Varcheh N., Aboofazeli R., IPSC2012, Isfahan, Iran.
6. Carbon-nanotube: A Promising Novel Nanoscale Drug Delivery System, **Hadidi N.**, Kobarfard F., Nafissi-Varcheh N., Aboofazeli R., IPSC2010, Zanjan, Iran
7. **Hadidi N.**, Nafissi-Varcheh N., Aboofazeli R. Optimization of Carbon Nanotubes PEGylation by Response Surface Methodology, 3rd International NanoBio Conference 2010, Zurich.
8. **Hadidi N.**, Nafissi-Varcheh N., Aboofazeli R. Optimization of Carbon Nanotubes PEGylation by Response Surface Methodology European Cells and Materials Vol. 20. Suppl. 3, 2010, 183
9. **Hadidi N.**, Nafissi-Varcheh N., Aboofazeli R., Carbon-nanotube: A Promising Novel Nanoscale Drug Delivery System, 12th Iranian Pharmaceutical Sciences Conference (IPSC 2010), Zanjan, Iran
10. **Hadidi N.**, Nazari N., Aboofazeli R., Optimization of Microemulsion-Based Organogels Containing Propranolol Hydrochloride Using Experimental Design Methods, 2nd International Conference on Drug Discovery & Therapy (ICDDT 2010), Dubai.
11. **Hadidi N.**, Nazari N., Aboofazeli R., Formulation and Optimization of Propranolol-Loaded Topical Organogels Using Modified Simplex and Central Composite Design, 11th Iranian Pharmaceutical Sciences Conference (IPSC 2008), Kerman, Iran
12. Bolourtchian N. ; **Hadidi N.** ; Foroutan S.M. Shafaghi B. Formulation of Pphysostigmine Ssalyclate Sublingual Tablet Using D-optimal Design, 11th Iranian Pharmaceutical Sciences Conference (IPSC 2008), Tehran, Iran
13. Mehravaran N., Mortazavi S.A., Moghimi H., **Hadidi N.**; Formulation and Evaluation of Physicochemical Characteristics and Mucoadhesivity of Formulated Artificial Saliva Containing Mucoadhesive Polymers; 12th Seminar of Iranian Pharmacy Students; 1-4 Nov. 2006, Sari, Iran
14. Sayyah M., **Hadidi N.**, Kamalinejad M., Analgesic and Anti-inflammatory Effect of Methanolic Extract of Lactuca Sativa in Formalin, Tail Flick and Inflammation Models, 6th National Congress of Medical Students, 2005, Sari, Iran
15. Salamzadeh J., **Hadidi N.**, Cytochrome450 and Important Clinical Drugs Interaction, Razi Monthly scientific magazine, 2006, 6(5):398-413.

16. Sayyah M., **Hadidi N.**, Kamalinejad M., Antinociceptive and Anti-inflammatory effect of Lactuca Sativa Extract in Formalin and Tail Flick Test, 2005, 6th National Congress of Iranian Medical Students, Sari, Iran
 17. **Hadidi N.** ; Foroutan S.M., Shafaati A., Improvement of Aqueous Solubility of Indomethacin for Eye Drop Formulation, 10th National Conference of Pharmaceutical Students, 2004, Mashhad, Iran.
 18. Sayyah M., **Hadidi N.**, Kamalinejad M., Antinociceptive Effect of Seed Extract of Scariola Sativa in Formalin test, 9th Iranian Congress of Pharmaceutical Students, 2003, Tehran, Iran
 19. Sayyah M., **Hadidi N.**, Kamalinejad M., Antinociceptive Effect of Seed Extract of Scariola Sativa in Formalin Test, 16th Iranian Congress of Physiology & Pharmacology, 2003, Tehran, Iran
-

References:

Reza Aboofazeli, Pharm. D., Ph. D.

Professor of Pharmaceutics, Department of Pharmaceutics, School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Vali-Asr-Niayesh junction, Tehran, Iran

E-mail: raoofazeli@sbmu.ac.ir or aboofazeli@yahoo.com

Tel: (0098) 21882000

Fax: (0098) 2188665317

Abbas Kebriaee zade, Pharm. D., Ph. D.

Professor of Pharmacology toxicology, Department of Pharmacology Toxicology Pharmacoeconomy and Pharmaceutical Management, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

E-mail: Kebriaee@tums.ac.ir

Tel: (0098) 2166482606 or 66801062

Fax: (0098) 2166482606 or 66801063

Farzad Kobarfard , Pharm. D., Ph. D.

Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, Shaheed Beheshti University of Medical Sciences , Vali-Asr-Niayesh junction, Tehran, Iran

E-mail: Farzadkf@yahoo.com

Tel: (0098) 2188200092

Fax: (0098) 2188665341

Farshad Hosseini Shirazi , Pharm. D., Ph. D.

Professor of Pharmacotoxicology , Department of Pharmacotoxicology, School of Pharmacy, Shaheed Beheshti University of Medical Sciences , Vali-Asr-Niayesh junction, Tehran, Iran

E-mail: fshirazi@yahoo.com

Tel: (0098) 2188200084

Fax: (0098) 218820084

Mehrdad Faizi: Pharm. D., Ph. D.

Professor of Pharmacology at SBMU and Life Science Senior Research Associate at Stanford Behavioral and Functional Neuroscience Laboratory (SBFNL), Stanford Medical School 1201 Welch Road, MSLS Building Stanford, CA 94305

Email: faizi64@stanford.edu or faizi64@yahoo.com

Tel: (408) 329-8522

Fax: (650) 330-4389